Should You Buy the Biogen Dip?

Should You Buy the Biogen Dip?

Biogen shares are plunging almost 30% Thursday. Is this a screaming buy opportunity or a giant red flag?

Here's Why Citigroup Says You Should Sell Micron Stock

Here's Why Citigroup Says You Should Sell Micron Stock

Some analysts are calling the day's optimism unwarranted.

Changes in Fed Policy Pressure Regional Banks

Changes in Fed Policy Pressure Regional Banks

How to trade BB&T, M&T Bank, PNC Financial, SunTrust and U.S. Bancorp as they decline on dovish moves by the Federal Reserve.

How to Play the Fed's Gift to the Markets (One Way Is With Netflix)

How to Play the Fed's Gift to the Markets (One Way Is With Netflix)

Wednesday was the first day that Netflix traded on above-average volume since Jan. 24.

Plug Power: Hope Is Not an Investment Strategy

Plug Power: Hope Is Not an Investment Strategy

Plug Power may not be a reliable source for investors hoping to capture some solid gains from the fuel cell battery maker's stock price.

Jim Cramer: Forgotten Companies Stocks' Are Leading the Way Up

Jim Cramer: Forgotten Companies Stocks' Are Leading the Way Up

Eclectic leadership is not the kind of leadership I can bank on.

Everybody Has a Levi's Story, But What Story Will the Levi's IPO Tell?

Everybody Has a Levi's Story, But What Story Will the Levi's IPO Tell?

Harmit Singh, CFO of Levi's, weighs in on the IPO.

Rite Aid Shareholders Approve Reverse Stock Split Plan

Rite Aid Shareholders Approve Reverse Stock Split Plan

Rite Aid's stock is trading below $1 and is in jeopardy of being delisted.

Tesla Sues Former Employee for Allegedly Stealing Autopilot Data - Report

Tesla Sues Former Employee for Allegedly Stealing Autopilot Data - Report

Tesla alleges that a former employee stole company data before switching jobs to work for a Chinese carmaker.

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.